sTRAIL/Apo2L (TNF-Related Apoptosis-Inducing Ligand/Apo2 Ligand)
TRAIL/Apo2L is a cytotoxic protein, which activates rapid apoptosis in tumor cells, but not in normal cells. TRAIL-induced apoptosis is achieved through binding to two death-signaling receptors, DR4 and DR5. These receptors belong to the TNFR superfamily of transmembrane proteins, and contain a cytoplasmic “death domain”, which activates the cell’s apoptotic machinery. The full length human TRAIL/Apo2L is a 281 amino acid protein, consisting of a 17 amino acid cytoplasmic domain, a 21 amino acid transmembrane domain, and a 243 amino acid extracellular domain. Recombinant Human soluble TRAIL/Apo2L is a 168 amino acid polypeptide (19.6 kDa), consisting of the TNF-homologous portion of the extracellular domain of the full length TRAIL/Apo2L protein.
- Species: Human
- Expression: E. coli Cell Expressed
- Assay 1: Typically 1-3 ng/mL ED50
- Typically 0.8-2.0 ng/mL ED50
- Purity: ≥98%
- Endotoxin: <1.0 EU/μg
- Molecular Mass: 19.6 kDa
- Formulation: 1x PBS
- Country of Origin: USA
This was determined by SDS-PAGE gel and HPLC analysis.
Assay#1: Determined by its ability to induce apoptotic cell death in TRAIL-sensitive U343MG cells.
Assay#2: Measured by its ability to induce apoptosis in LN-18 cells (human glioblastoma cells).
Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.5-1.0 mg/ml. Do not vortex.
For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% HSA) and store in working aliquots at -20°C to -80°C.